Lenalidomide Thorton & Ross Ltd.

Lenalidomide, the active ingredient in Lenalidomide Thorton & Ross Ltd., is an immunomodulatory agent presented as an oral tablet for oral use. It is employed in the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Thorton & Ross Ltd. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple Myeloma: improves disease control and prolongs survival in adult patients. Myelodysplastic Syndromes: reduces transfusion dependence and improves blood cell counts.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Neutropenia - Thrombocytopenia - Fatigue - Diarrhea

Serious or Rare Side Effects: - Venous thromboembolism - Severe cutaneous reactions such as Stevens‑Johnson syndrome - Development of secondary primary malignancies

Lenalidomide requires careful monitoring and risk mitigation.

Monitor blood counts regularly: detect neutropenia, anemia, or thrombocytopenia. Assess thromboembolic risk: consider prophylactic anticoagulation when indicated. Avoid use in pregnancy: teratogenic potential requires strict contraception. Use contraception: both male and female patients must employ effective methods. Adjust dose in renal impairment: follow prescriber guidance for reduced clearance. Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure. - Strong CYP3A4 inducers (e.g., rifampin) may reduce effectiveness. - Anticoagulants (e.g., warfarin) may heighten bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase renal toxicity. - Hormonal contraceptives: efficacy may be reduced, requiring alternative methods.